Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Industry Feature

Unraveling Hereditary ATTR Amyloidosis: Key Variants and Clinical Insights

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Tune in to hear expert insights on common variants and clinical presentations of hereditary transthyretin-mediated amyloidosis.

  • Sponsored by

  • Overview

    Based on the THAOS Registry, 47 different gene variants of polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) have been reported in the US, and the three most common variants are V122I at about 45 percent, T60A at 20 percent, and V30M at 6 percent.1 Joining Dr Jennifer Caudle to discuss the clinical presentations of those three variants and the importance of assessing patients for both polyneuropathy and cardiomyopathy are Drs Thomas Brannagan and Nitasha Sarswat. Dr Brannagan is the Director of both the Peripheral Neuropathy Center and the Columbia Neuropathy Research Center at Columbia University in New York, and Dr Sarswat is the Director of Infiltrative Cardiomyopathy at the University of Chicago.

    Reference:

    1. Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68:161-172. 

    ©2024 AstraZeneca. All rights reserved.
    US-93599 Last Updated 11/24

Schedule14 Dec 2024